⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
India has one of the highest rates of thyroid disease in the world. According to the Indian Thyroid Society, approximately 42 million Indians suffer from thyroid disorders — and hypothyroidism disproportionately affects women and people with obesity, the same population most likely to be prescribed GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound).
If you have a thyroid condition and your doctor is considering GLP-1 therapy, this guide explains what you need to know — including the drug interactions, the monitoring required, and what that thyroid cancer warning on the label actually means.
Consult your healthcare provider before starting any medication, especially if you have a thyroid condition.
This guide is written for people with hypothyroidism (underactive thyroid) on levothyroxine who are also considering or currently on GLP-1 medications, people with hyperthyroidism or Graves disease managing weight or diabetes, people with Hashimoto's thyroiditis concerned about potential interactions, people who have had partial or total thyroidectomy, and anyone who has seen the thyroid cancer warning on their GLP-1 medication label and wants to understand it properly.
GLP-1 receptors are found throughout the body — including in the thyroid gland. In animal studies using rats and mice, semaglutide and other GLP-1 agonists caused C-cell thyroid tumours (medullary thyroid carcinoma in rodents). This triggered the black box warning that now appears on all GLP-1 medication labels.
Important context: The rodent C-cell tumours are considered species-specific. Human thyroid C-cells have far fewer GLP-1 receptors than rodent C-cells. Multiple large clinical trials involving tens of thousands of patients — including the SUSTAIN and PIONEER trial programmes — have not found a statistically meaningful increase in medullary thyroid cancer in humans taking GLP-1 medications.
However, because the risk cannot be completely excluded, GLP-1 medications remain contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).
For the vast majority of people with common hypothyroidism or Hashimoto's thyroiditis, the thyroid cancer warning does not apply.
For people with hypothyroidism on levothyroxine, there are two critical pharmacological interactions:
GLP-1 medications slow gastric emptying. Levothyroxine is typically taken on an empty stomach 30–60 minutes before food because food significantly reduces its absorption. GLP-1-induced gastric slowing may further impair levothyroxine absorption — meaning your thyroid control can worsen even if you are taking the same dose you have always taken.
Weight loss changes your levothyroxine requirement. Levothyroxine dosing is partly based on body weight. As you lose significant weight on GLP-1 therapy — often 10–15% of body weight over one year — your levothyroxine requirement decreases. Staying on the same dose with a lower body weight can lead to subtle hyperthyroid symptoms including palpitations, anxiety, insomnia, and long-term bone density concerns.
A landmark study published in the Indian Journal of Endocrinology and Metabolism found that hypothyroidism affects approximately 10.95% of Indian adults, with higher rates in women, people with obesity, and those in iodine-deficient regions including parts of the Himalayan belt and Northeast India. Many people with undiagnosed hypothyroidism struggle with weight gain — which then brings them to a doctor who prescribes GLP-1 medications.
Indian diets vary considerably in iodine content. Iodised salt is widely available but not universally used. Patients with thyroid conditions on GLP-1 therapy should not restrict iodised salt unless specifically advised by their endocrinologist.
Step 1: Disclose your complete thyroid history before starting GLP-1 therapy. Tell your prescribing doctor your diagnosis, current medications and doses, previous thyroid surgery or radioactive iodine treatment, and any family history of medullary thyroid cancer or MEN2 syndrome.
Step 2: Get a baseline thyroid panel. Before starting, get TSH, Free T4, and Free T3 checked. Add Anti-TPO antibodies if Hashimoto's is suspected or not yet formally diagnosed.
Step 3: Recheck TSH at 6–8 weeks after starting GLP-1 therapy. Gastric slowing may reduce levothyroxine absorption enough to shift your TSH. This is the most important early check.
Step 4: Monitor TSH every 3 months during active weight loss. As your body weight falls on GLP-1 therapy, your levothyroxine dose will likely need downward adjustment. Plan regular monitoring rather than waiting for symptoms.
Step 5: Take levothyroxine at the correct time. Take levothyroxine first thing in the morning on an empty stomach and wait 30–60 minutes before eating. Avoid taking levothyroxine near calcium supplements, iron tablets, or antacids such as Gelusil or Digene — these significantly impair absorption and are a very common problem in India where self-medication with antacids is widespread. Space them at least 4 hours apart.
Step 6: Know which symptoms to watch for as weight changes.
Signs your levothyroxine dose may be too high after weight loss: heart palpitations, tremors, excessive sweating, difficulty sleeping, unexplained anxiety, feeling too hot.
Signs your dose may have become insufficient: persistent fatigue, cold intolerance, new constipation, unexplained hair loss, weight loss stalling despite good adherence to GLP-1 therapy.
Step 7: Report any neck symptoms promptly. If you develop a neck lump, persistent hoarseness, difficulty swallowing, or neck pain while on GLP-1 therapy, contact your doctor for evaluation including thyroid ultrasound.
Not informing your endocrinologist that you started a GLP-1 medication. Many Indians see a separate endocrinologist for thyroid disease and a different physician for diabetes or weight management. These doctors may not communicate. You must inform both.
Assuming levothyroxine dose stays the same forever. Weight loss of even 8–10 kg can necessitate a dose reduction. Failure to adjust increases cardiac risk over the long term.
Self-adjusting thyroid medication based on symptoms alone. Always test TSH before adjusting dose. Symptoms overlap with many other conditions and can mislead.
Taking iron or calcium near levothyroxine. Extremely common in India — iron for anaemia, calcium for bone health. Both severely impair levothyroxine absorption. Space them by 4 hours minimum.
Stopping GLP-1 medication because of the cancer warning without discussion. For most people with ordinary hypothyroidism, the GLP-1 thyroid warning is not relevant. Stopping therapy unilaterally wastes the benefit. Always discuss actual risk-benefit with your endocrinologist.
Contact your doctor urgently if you notice a new or growing lump in your neck, persistent hoarseness not explained by a cold or throat infection, difficulty swallowing that is new, shortness of breath that is unexplained, or severe palpitations with chest discomfort.
I have Hashimoto's thyroiditis. Can I still take Ozempic or Mounjaro? Hashimoto's is autoimmune hypothyroidism and is not a contraindication for GLP-1 therapy. Your TSH and antibody levels should be monitored. Discuss with your endocrinologist before starting.
My TSH was normal before starting Mounjaro. Why did it change? GLP-1-induced gastric slowing can reduce levothyroxine absorption, changing the amount of hormone reaching your bloodstream. A dose review with your endocrinologist is appropriate.
I had my thyroid removed. Am I at higher risk from GLP-1 medications? The thyroid C-cell cancer risk is not applicable after a total thyroidectomy since the gland has been removed. You still need careful monitoring of your levothyroxine dose as your weight changes.
Can GLP-1 medications help reduce Hashimoto's inflammation? There is emerging research suggesting GLP-1 agonists may have anti-inflammatory effects. However, this is not an established treatment indication. Do not start GLP-1 medications solely for this purpose.
Having a thyroid condition does not prevent you from benefiting from GLP-1 medications. Millions of Indians have both thyroid disease and diabetes or obesity — and many are on GLP-1 therapy safely. The key is coordination between all your treating doctors, regular TSH monitoring, awareness of how weight loss affects levothyroxine requirements, and avoiding common absorption mistakes.
With proper monitoring and communication, most thyroid patients can use GLP-1 medications safely and effectively.
Consult your healthcare provider before starting any medication, and inform all your doctors about every medication you take.
